Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-04
2006-07-04
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S167000, C549S055000, C562S442000
Reexamination Certificate
active
07071225
ABSTRACT:
Arylaminopropane analogues are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of the present invention.
REFERENCES:
patent: 4690931 (1987-09-01), Wick et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5422368 (1995-06-01), Sternschantz et al.
patent: 5494928 (1996-02-01), Bös
patent: 5571833 (1996-11-01), Kruse et al.
patent: 5578612 (1996-11-01), Macor et al.
patent: 5874477 (1999-02-01), McConnell et al.
patent: 5889052 (1999-03-01), Klimko et al.
patent: 5902815 (1999-05-01), Olney et al.
patent: 6548493 (2003-04-01), Robichaud et al.
patent: 6552017 (2003-04-01), Robichaud et al.
patent: 6713471 (2004-03-01), Robichaud et al.
patent: 2004/0034015 (2004-02-01), Robichaud et al.
patent: 0771563 (1997-05-01), None
patent: WO 92/20338 (1992-11-01), None
patent: WO 94/13275 (1994-06-01), None
patent: WO 97/33579 (1997-09-01), None
patent: WO 98/18458 (1998-05-01), None
patent: WO 98/31354 (1998-07-01), None
patent: WO 00/12475 (2000-03-01), None
patent: WO 00/12510 (2000-03-01), None
patent: WO 00/16761 (2000-03-01), None
patent: WO 00/35922 (2000-06-01), None
patent: WO 00/44753 (2000-08-01), None
Clare et al., Journal of Medicinal Chemistry, vol. 41, No. 20 (1998).
Ichiro et al., “Studies on the synthesis of 2-substituted-1-naphthols and 7-substituted-8-quinolinols,”Chem. Abstr.vol. 108, 186616g, pp. 695 (1988).
Horii et al., “Synthetic Studies on Anthracyclinones, IX Lithiation of N,N-Dimethyl-napththalenemethylamines and a New Synthetic Pathway to 2,3-Napthalides,”Chem. Pharma. Bull.Vo. 19(6), pp. 1245-1256 (1971).
IOVS,Aqueous Humor Dynamics I, vol. 39(4), S488, 2236-B93, (1998).
Glennon, et al., “Binding of Substituted and Conformationally Restricted Derivatives of N-(3-Phenyl-n-propyl)-1-phenyl-2-aminopropane at σ-Receptors,”J. Med. Chem, vol. 34, pp. 855-1859 (1991).
R. Howe, “β-Adrenergic Blocking Agents. VI, Pronethalol and Propranolol Analogs with Alkyl Substituents in the Alkanol Side Chain.”J. Med. Chem.vol. 12, pp. 642-646 (1969).
Govindachari et al., “Synthesis of 3-Methyl Isoquinolines,”J. Org. Chem.vol. 18, pp. 1253-1262 (1953).
Griffin, et al., “Pharmacological Characterization of an FP Prostaglandin Receptor on Rat Vascular Smooth Muscle Cells (A7r5) Coupled to Phosphoinositide Turnover and Intracellular Calcium Mobilization,”J. Pharmacol. Expt. Ther.vol. 286, pp. 411-418 (1998).
Johnson et al., Binding to the Serotonin 5-HT2 Receptor by the Enantiomers of 125I-DOI,Neuropharmacology, vol. 26, No. 12, pp. 1803-1806 (1987).
Osborne, et al. “Do Beta-Adrenoceptors and Serotonin 5-HTIAReceptors Have Similar Functions in the Control of Intraocular Pressure in the Rabbit?”Ophthalmologica, vol. 210, pp. 308-314 (1996).
Fiorella, “Role of 5-HT2Aand 5-HT2Creceptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives,”Psychopharmacology, vol. 121:357-363, 1995.
Bowen et al., “Nonlinear regression using spreadsheets,”Trends Pharmacol. Sci., vol. 16, pp. 413-417 (1995).
Wang, et al., “Effect of 5-methylurapidil, an α1a-adrenergic antagonist and 5-hydroxytryptamine1aagonist, on aqueous humor dynamics in monkeys and rabbits”Current Eye Research, vol. 16(8) pp. 769-775 (1997).
Nabih, et al.. “Synthesis of (Heterocyclicamino) aminoalkylnaphthols and Reduced Tetrahydro Derivatives for Possible Antimalarial Activity,” J. of Pharm. Sciences, vol. 61, No. 9, pp. 1500-1501 (1972).
Clare, “The Frontier Orbital Phase Angles: Novel QSAR Descriptors for Benzene Derivatives, Applied to phenylalkylamine Hallucinogens,” J. Med. Chem. vol. 41, pp. 3845-3856 (1998).
International Search Report for PCT/US02/16842 dated Aug. 19, 2002.
Shulgin et al., “A chemical love story,” Transform Press, Berkeley, CA (1991), #86, reprinted online at www.erowid.org/library/books—online/pihkal/pihlal086.
Hellberg Mark R.
Namil Abdelmoula
Alcon Inc.
Kilyk & Bowersox P.L.L.C.
Saeed Kamal A.
LandOfFree
Arylaminopropane analogues and their use for the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylaminopropane analogues and their use for the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylaminopropane analogues and their use for the treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3610639